Study: Avastin, docetaxel combo stalls breast cancer progression

02/12/2008 | NYTimes.com · TheStreet.com

A study involving 736 women found that the combination of Genentech's cancer drug Avastin and docetaxel chemotherapy extended progression-free survival in breast cancer patients who have not undergone chemotherapy. The new study, sponsored by Genentech shareholder Roche Holding, may shore up the drug's chances for FDA approval as a breast cancer drug.

View Full Article in:

NYTimes.com · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ